You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Stiripentol - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for stiripentol and what is the scope of freedom to operate?

Stiripentol is the generic ingredient in one branded drug marketed by Biocodex Sa and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for stiripentol
US Patents:0
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 74
Clinical Trials: 13
Patent Applications: 1,595
What excipients (inactive ingredients) are in stiripentol?stiripentol excipients list
DailyMed Link:stiripentol at DailyMed
Recent Clinical Trials for stiripentol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zogenix, Inc.Phase 3
University Health Network, TorontoPhase 3
BiocodexPhase 4

See all stiripentol clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for stiripentol

US Patents and Regulatory Information for stiripentol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-002 Aug 20, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-001 Aug 20, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-002 Aug 20, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biocodex Sa DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223-001 Aug 20, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Biocodex Sa DIACOMIT stiripentol CAPSULE;ORAL 206709-001 Aug 20, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for stiripentol

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocodex Diacomit stiripentol EMEA/H/C/000664
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Authorised no no no 2007-01-03 2009-02-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.